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Abstract
Introduction: The purpose of this observational study was to analyze the rates, characteristics and associated risk
factors of severe infections in patients with systemic autoimmune diseases (SAD) who were treated off-label with
biological agents in daily practice.
Methods: The BIOGEAS registry is an ongoing Spanish prospective cohort study investigating the long-term safety
and efficacy of the off-label use of biological agents in adult patients with severe, refractory SAD. Severe infections
were defined according to previous studies as those that required intravenous treatment or that led to
hospitalization or death. Patients contributed person-years of follow-up for the period in which they were treated
with biological agents.
Results: A total of 344 patients with SAD treated with biological agents off-label were included in the Registry until
July 2010. The first biological therapies included rituximab in 264 (77%) patients, infliximab in 37 (11%), etanercept in 21
(6%), adalimumab in 19 (5%), and ‘other’ agents in 3 (1%). Forty-five severe infections occurred in 37 patients after a
mean follow-up of 26.76 months. These infections resulted in four deaths. The crude rate of severe infections was 90.9
events/1000 person-years (112.5 for rituximab, 76.9 for infliximab, 66.9 for adalimumab and 30.5 for etanercept
respectively). In patients treated with more than two courses of rituximab, the crude rate of severe infection was 226.4
events/1000 person-years. A pathogen was identified in 24 (53%) severe infections. The most common sites of severe
infection were the lower respiratory tract (39%), bacteremia/sepsis (20%) and the urinary tract (16%). There were no
significant differences relating to gender, SAD, agent, other previous therapies, number of previous immunosuppressive
agents received or other therapies administered concomitantly. Cox regression analysis showed that age (P = 0.015)
was independently associated with an increased risk of severe infection. Survival curves showed a lower survival rate in
patients with severe infections (log-rank and Breslow tests < 0.001).
Conclusions: The rates of severe infections in SAD patients with severe, refractory disease treated depended on the
biological agent used, with the highest rates being observed for rituximab and the lowest for etanercept. The rate of
infection was especially high in patients receiving three or more courses of rituximab. In patients with severe infections,
survival was significantly reduced. Older age was the only significant predictive factor of severe infection.
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In recent decades, the standard of care for patients with
systemic autoimmune diseases (SAD) has been based on
corticosteroids and immunosuppressive agents, although
scientific evidence of their efficacy and safety relies prin-
cipally on data from uncontrolled studies. The complex-
ity of therapy in patients with SAD is increased by the
large number of patients who do not respond to first-
line therapies and those who relapse after initial clinical
remission. In these patients, there is even less scientific
evidence available for the use of second-line drugs,
which are often prescribed according to individual clini-
cal decisions. The emergence of biological therapies has
increased the therapeutic armamentarium available in
these complex situations. These therapies are used for a
rapidly increasing number of cases of SAD [1] even
though they are not yet licensed for this use by the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA). This off-label use is mainly
employed to treat patients with either life-threatening
situations, or severe involvement refractory or intolerant
to standard therapy.
The risk of severe infection is a key factor in assessing
the risks and benefits of using biologic agents to treat
patients with SAD, especially as the use is off-label.
Available data on the safety of biologic agents in SAD
come from some randomized controlled trials (RCTs)
and, especially, from a large number of small observa-
tional studies and case reports [2]. In RCTs, the preva-
lence of severe infection is less than 10% [3-16], but it is
unclear whether the safety data obtained in these trials
can be extrapolated to clinical practice. In RCTs,
patients with associated processes or comorbidities are
often excluded, meaning that the patient population
tested is clearly different from patients treated in real-
life conditions, in which biologic therapy is often more
prolonged and patients have usually received long prior
courses of corticosteroids and immunosuppressive
agents. There is little information on the rate of severe
infections in large series of patients with SAD treated
off-label with biologic agents in clinical practice [17,18].
The purpose of this observational study was to analyze
the rates, characteristics, and associated risk factors of
severe infections in patients with SAD treated off-label
with biologic agents in daily practice.
Materials and methods
Registry
The BIOGEAS (Spanish Study Group of Biological
Agents in Autoimmune Diseases) registry is an ongoing
Spanish prospective cohort study which since 2002 has
been investigating the long-term safety and efficacy of
the off-label use of biologic agents in adult patients with
severe, refractory SAD [17]. By July 2010, the database
included 344 patients reported by 21 Spanish depart-
ments of internal medicine. The SAD includes systemic
lupus erythematosus (SLE), Sjögren syndrome, systemic
sclerosis, polymyosistis, dermatomyositis, polyarteritis
nodosa, Wegener granulomatosis, Churg-Strauss vasculi-
tis, microscopic polyangiitis, giant cell arteritis, cryoglo-
bulinemia, Behçet disease, sarcoidosis, adult-onset Still
disease, antiphospholipid syndrome, relapsing polychon-
dritis, idiopathic thrombocytopenic purpura, antisynthe-
tase syndrome, and rheumatic polymyalgia. Diagnosis of
SAD is based on the current international classification
criteria for each disease. The inclusion criteria are: i)
severe disease, defined as the development of potentially
life-threatening clinical manifestations; or ii) refractory
disease, defined as patients not achieving remission or
relapsing, or patients with progressive disease despite
optimal doses of corticosteroids and who have failed
with at least two consecutive therapies considered as the
standard of care for the corresponding autoimmune
disease.
Data collection
Data were collected at baseline (time of first administra-
tion of the drug), at six months and then every 12
months or at disease relapse, using an electronic case
report form. To minimize possible interobserver bias,
the inclusion criteria and variables of the protocol were
agreed by all participating centers. The study was
approved by the Ethics Committee of the coordinating
center (Hospital Clinic, Barcelona, Spain) and then by
each participating center. Written informed consent was
obtained from all patients.
Baseline assessment
Baseline information was collected on all patients in the
BIOGEAS registry at the initiation of biologic therapy
and included demographic data, disease duration, pre-
vious therapies, biologic agent, dosage, number of infu-
sions/subcutaneous administrations, concomitant drugs,
therapeutic response, relapses, retreatments and
switches, adverse events, and outcomes.
Definition of severe infection
Severe infections were defined according to previous
studies [19,20] as those that required intravenous treat-
ment or that led to hospitalization or death. Infections
were classified by anatomic site and by microorganism.
Statistical analysis
Patients contributed person-years of follow up for the
period in which they were treated with biologic agents.
Patients who later switched to other biologic agents, in
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tered therapy, and patients who were re-treated, contrib-
uted separate events and person-years for each different
drug or therapy cycle; person-years were calculated
from the first day of administration of the biologic agent
to the date of the last administered dose until July 2010,
drug discontinuation, or death. In patients who discon-
tinued biologic therapy, infection rates were calculated
according to an exposure period-at-risk model used in
recent studies in rheumatic diseases [19,20]. This type
of model is in line with the recent European League
Against Rheumatism (EULAR)recommendations on the
reporting of safety data in biologic registers [21], in
order to address the possible impact of an ongoing attri-
butable risk beyond the drug discontinuation date [21].
This model consists of adding a lag window period
which, in our study, was defined according to the biolo-
gic agent used. For rituximab, infections were included
if they occurred during the 12 months after each infu-
sion (initial treatment and/or each subsequent infusion)
[18]. For the remaining agents, overwhelmingly anti-
TNF agents, the exposure period was defined as the
active treatment period plus a 90-day lag window [19].
Rates of serious infections are presented as events/1,000
person-years and 95% confidence intervals (CIs). Categori-
cal data were compared using the chi squared and Fisher’s
exact tests. Continuous variables were analyzed with the
Student’s t-test in large samples of similar variance, with
results indicated as mean * standard error of the mean
(SEM), and with the nonparametric Mann-Whitney U-test
for small samples, with results indicated as median and
interquartiles. A two-tailed value of P < 0.05 was taken to
indicate statistical significance. When independent vari-
ables appeared to have statistical significance in the uni-
variate analysis, they were included in a multivariate Cox
regression analysis using a backward stepwise method
allowing adjustment for the variables that were statistically
significant (P < 0.05) in the univariate analysis. The hazard
ratios (HR) and their 95% CI obtained in the adjusted
regression analysis were calculated. Kaplan-Meier survival
curves of patients with and without severe infections were
compared using the log-rank and Breslow tests. The statis-
tical analysis was performed using the SPSS program (IBM
SPSS Statistics 19.0).
Results
Baseline characteristics
The baseline characteristics are shown in Table 1. A
total of 344 patients with SAD treated with biologic
agents off-label were included in the registry until July
Table 1 Baseline characteristics of 344 patients with
systemic autoimmune diseases treated with biological
agents
n = 344
Females 270 (78%)
Mean age (years) 42.74 ± 0.83
Mean time of follow up (months) 26.76 ± 1.14 (0.5-105)
Autoimmune diseases
- Systemic lupus erythematosus 140 (41%)
- Systemic vasculitis 50 (14%)
- Inflammatory myopathies 38 (11%)
- Behçet disease 31 (9%)
- Sjögren syndrome 23 (7%)
- Other diseases* 62 (18%)
Previous therapies (ever exposed)
- Oral corticosteroids 332 (97%)
- Methylprednisolone pulses 86 (25%)
- Immunosuppressants 282 (82%)
- Intravenous immunoglobulins 89 (26%)
- Plasma exchange 10 (3%)
- Other therapies 109 (32%)
Cumulated dose/length of previous therapies
- Mean length of prednisone therapy (years) 8.04 ± 0.65
- Cumulated dose of cyclophosphamide (gr) 7.18 ± 1.11
- Mean length of mycophenolate (years) 2.20 ± 0.39
- Mean length of azathioprine (years) 1.44 ± 0.35
- Number of previous immunosuppressants
> = 3 73 (21%)
> = 4 25 (7%)
Biological agent
- Rituximab 264 (77%)
- Infliximab 37 (11%)
- Etanercept 21 (6%)
- Adalimumab 19 (5%)
- Other 3 (1%)
Therapies administered concomitantly
- Oral corticosteroids 312 (91%)
- Immunosuppressants 193 (56%)
- Intravenous immunoglobulins 14 (4%)
- Plasma exchange 11 (3%)
Time of exposure to biological (person-years)
- Total time 495
- Exposure to rituximab 328
- Exposure to infliximab 52
- Exposure to etanercept 66
- Exposure to adalimumab 30
Retreatment 55 (16%)
Switch 33 (10%)
See the complete list of diseases included in the Methods section.
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Page 3 of 102010. There were 270 (78%) women and 74 (22%) men,
with a mean age of 42.74 ± 0.83 (range 16 to 82) years.
The main SAD were SLE in 140 (41%) cases, systemic
vasculitis in 50 (14%), inflammatory myopathies in 38
(11%), Sjögren syndrome in 23 (7%), and Behçet dis-
ease in 31 (9%). Previous therapies included corticos-
teroids in 332 (97%) cases, cyclophosphamide in 172
(50%), methotrexate in 109 (32%), mycophenolate in
98 (28%), azathioprine in 97 (28%), and intravenous
immunoglobulins in 89 (26%). Biologic therapies were
administered due to life-threatening situations in 48
(14%) patients. The first biologic therapy included
rituximab in 264 (77%) patients, infliximab in 37
(11%), etanercept in 21 (6%), adalimumab in 19 (5%),
and other agents in 3 (1%). Concomitant therapies are
summarized in Table 1. Sixty-one (18%) patients were
treated with two courses of biologics, 14 (4%) with
three courses and 8 (2%) with four courses. In 33
(10%) patients, the first biologic agent was switched to
another agent.
Rates of severe infections
Forty-five severe infections, which required hospitaliza-
tion and/or intravenous antibiotics and/or resulted in
death, occurred in 37 patients after a mean follow up of
26.76 months (six patients had two or more severe
infections). Infections occurred during the first six
months after initiation of therapy (63%), between
months 6 and 12 of therapy (13%), and after one year of
initiation of therapy (24%). These infections resulted in
four deaths. The crude rate of severe infections was 90.9
events/1,000 person-years (95% CI 66.31 to 121.64). The
crude rates of serious infections according to treatment
were 112.5 events/1,000 person-years for rituximab (95%
CI 79.20 to 155.10), 76.9 events/1,000 person-years for
infliximab (95% CI 20.96 to 196.95), 66.9 events/1,000
person-years for adalimumab (95% CI 8.10 to 241.55)
and 30.5 events/1,000 person-years for etanercept (95%
CI 3.69 to 110.02; Table 2). The crude rates of serious
infections were 90.2 events/1,000 person-years for
refractory patients (95% CI 25.80 to 365.30) and 94.8
Table 2 Rates of all severe infections, according to agent, number of courses, and main autoimmune diseases
Patients Person-years Number of infections Rate of infections/
1,000 person-years
95% Confidence interval
TOTAL 344 495 45 90.90 66.31 to 121.64
RITUXIMAB
- Total 264 328.83 37 112.52 79.20 to 155.10
- First course 211 252.17 30 119.00 88.03 to 169.80
- Second course 38 54.58 2 36.64 4.44 to 132.37
- Third or subsequent courses 15 22.08 5 226.40 73.50 to 528.50
ANTI-TNF AGENTS
- Total 77 147.58 8 54.21 23.40 to 106.81
- Infliximab 37 52.00 4 76.92 20.96 to 196.95
- Adalimumab 19 29.91 2 66.85 8.10 to 241.55
- Etanercept 21 65.67 2 30.46 3.69 to 110.02
DISEASES
- SLE 140 175.42 11 62.71 31.30 to 112.20
- Systemic vasculitis 50 74.75 11 147.16 73.50 to 263.30
- Inflammatory myopathies 38 60.42 7 115.86 46.60 to 238.70
- Behçet disease 31 61.25 2 32.65 3.95 to 117.95
- Sjögren syndrome 23 31.92 3 93.98 19.38 to 274.66
DISEASE/AGENT
- Behçet disease/IFX 20 36.50 1 27.39 0.68 to 152.65
- Cryoglobulinemia/RTX 15 14.17 4 282.30 76.90 to 722.80
- Wegener granulomatosis/RTX 18 29.00 4 137.90 37.60 to 353.20
- SLE/RTX 139 171.08 11 64.30 32.09 to 115.04
- Inflammatory myopathies/RTX 27 32.17 2 62.18 7.53 to 224.61
- Sjögren syndrome/RTX 21 24.00 3 125.00 25.80 to 365.30
INDICATION
- Refractory disease 296 421.17 38 90.22 63.85 to 123.84
- Life-threatening situation 48 73.83 7 94.81 38.12 to 195.35
IFX, infliximab; RTX, rituximab; SLE, systemic lupus erythematosus.
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life-threatening situations (95% CI 38.12 to 195.35).
The crude rates of serious infections according to
SAD were 147.2 events/1,000 person-years for systemic
vasculitis (95% CI 73.50 to 263.30), 115.9 events/1,000
person-years for inflammatory myopathies (95% CI
46.60 to 238.70), 94.0 events/1,000 person-years for
Sjögren syndrome (95% CI 19.38 to 274.66), 62.7 events/
1,000 person-years for SLE (95% CI 31.30 to 112.20),
and 32.6 events/1,000 person-years for Behçet disease
(95% CI 3.95 to 117.95). Table 2 also includes the crude
rates for the six most frequent disease/biologic agent
combinations reported.
Retreatment and switches
We analyzed the percentage and rates of severe infec-
tions in patients treated with more than one course of
r i t u x i m a b .T h ep e r c e n t a g eo fi n f e c t i o nw a s2 5o f2 6 4
(9%) in the first course, 2 of 38 (5%) in the second
course and 3 of 15 (20%) in the third and subsequent
courses; the crude rates were 119.0, 36.6, and 226.4
events/1,000 person-years, respectively. Severe infections
occurred in 2 of 33 (6%) patients in whom the biologic
agent was switched.
Pathogens
A pathogen was identified in 24 (53%) severe infections.
Bacterial infections included Streptococcus pneumoniae
(n =3 ) ,Escherichia coli (n =3 ) ,Staphylococcus aureus
(n = 3), Pseudomonas aeruginosa (n = 2), Staphylococcus
sp (n = 1), Stenotrophomonas maltophilia (n = 1), Enter-
ococcus faecalis (n =1 ) ,Corynebacterium (n =1 ) ,a n d
Proteus mirabillis (n = 1). Viral infections included cyto-
megalovirus (n = 3), and herpes simplex virus (n =1 ) .
Fungal infections included candidiasis (n = 2), aspergil-
losis (n = 1), and Pneumocystis jiroveci infection (n = 1).
There were three bacterial intracellular infections: Myco-
bacterium tuberculosis (n =2 )a n dListeria monocyto-
genes (n = 1). Multibacterial infection was reported in
one patient.
Site of infection
The most common site of severe infection was the lower
respiratory tract (39%), bacteriemia/sepsis (20%), the
urinary tract (16%), the skin and soft tissues (9%), the
gastrointestinal tract (5%), the central nervous system
(5%), upper respiratory tract (5%), and the bones and
joints (2%). Five (13%) patients presented separate infec-
tions in different sites.
Risk factors for severe infections
Univariate analysis showed that patients who developed
severe infections were older (49.14 vs 41.97 years, P =
0.008), had received methylprednisolone pulses less
frequently (11% vs 27%, P = 0.043) and were treated
concomitantly with cyclosporine A/tacrolimus more fre-
quently (13% vs 5%, P =0 . 0 4 1 )i nc o m p a r i s o nw i t h
patients without severe infections (Table 3). There were
no significant differences according to gender, SAD,
agent, other previous therapies, number of previous
immunosuppressive agents received, and other therapies
administered concomitantly (Table 3). Multivariate Cox
regression analysis showed that age (HR 1.026, 95% CI
1.005-1.047, P = 0.014) was significantly associated with
an increased risk of severe infection.
Mortality
Figure 1 shows the survival curves of patients according
to the development or not of severe infections (log-rank
and Breslow tests < 0.001).
Discussion
Biologic agents are currently used in patients with
severe, refractory SAD even though they are not yet
licensed for this use. Available scientific evidence comes
from various RCTs but principally from a large number
of observational studies and case reports. However, the
results of uncontrolled studies and, especially, case
reports may overstate the efficacy and understate the
risks, due to the positive reporting and publication bias.
One of the main concerns of the use of biologic agents
is the potential risk of severe infections in patients with
severe, refractory disease and a long-term history of the
use corticosteroids and immunosuppressive agents,
which per se increases the risk of infection. The best evi-
dence on the safety of biological agents in SAD come
from RCTs. In a pooled analysis of RCTs published to
date (Table 4) [3-16], the global percentage of adverse
events was significantly higher in patients receiving bio-
logic agents in comparison with those receiving placebo
(59.4% vs 48.7%, P < 0.001, HR 1.54, 95% CI 1.20-1.97).
However, there were no significant differences either in
the percentage of total number of infections (30.7% vs
29.9%, P = 0.79) or the percentage of severe infections
(8.3% vs 7.6%, P = 0.69). However, the prevalence and
rates of severe infections in SAD patients treated with
biologic agents off-label in clinical practice has not yet
been determined. For this reason, the Spanish Society of
Internal Medicine set up a national multicenter prospec-
tive registry intended to determine the tolerance to and
efficacy of biologic agents in clinical practice. The
results of the present study show that 11% of patients
developed severe infections, with a crude rate of 91
severe infections/1,000 person-years.
The highest rate of severe infections was observed in
SAD patients treated with rituximab, which was used in
nearly 80% of our patients, the majority of whom had
SLE, systemic vasculitis, or Sjogren syndrome. Since its
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Page 5 of 10Table 3 Main baseline characteristics of patients who developed severe infections in comparison with those who did
not
Severe infection
n =3 7
No severe infection
n = 307
Bilateral P value
Females 32 (86%) 238 (77%) 0.289
Mean age (years) 49.14 ± 2.77 41.97 ± 0.86 0.008*
Autoimmune diseases
- Systemic lupus erythematosus 11 (30%) 129 (42%)
- Systemic vasculitis 8 (22%) 42 (14%)
- Inflammatory myopathies 6 (16%) 32 (16%) 0.459
- Behçet disease 2 (5%) 29 (9%)
- Primary Sjögren’s syndrome 2 (5%) 21 (7%)
- Other diseases 8 (22%) 54 (18%)
Previous therapies (ever exposed)
- Oral corticosteroids 35 (95%) 297 (97%) 0.377
- Methylprednisolone pulses 4 (11%) 82 (27%) 0.043
- Cyclophosphamide 23 (62%) 149 (48%) 0.163
- Mycophenolate 12 (32%) 86 (28%) 0.567
- Azathioprine 6 (16%) 91 (30%) 0.120
- Methotrexate 12 (32%) 97 (32%) 1.000
- Intravenous immunoglobulins 6 (16%) 83 (27%) 0.171
Cumulated dose/length of previous therapies
- Mean length of prednisone therapy (years) 9.50 ± 2.89 7.93 ± 0.67 0.540
- Cumulated dose of cyclophosphamide (gr) 9.00 7.00 ± 1.20 0.629
- Mean length of mycophenolate (years) 0.96 ± 0.79 2.39 ± 0.44 0.236
- Mean length of azathioprine (years) 0.38 ± 0.28 1.56 ± 0.39 0.324
- Number of previous immunosuppressants
> = 3 5 (13%) 68 (22%) 0.289
> = 4 2 (5%) 23 (7%) 1.000
Biological agent
- Rituximab 29 (78%) 235 (76%)
- Infliximab 4 (11%) 33 (11%)
- Etanercept 2 (5%) 19 (6%) 0.982
- Adalimumab 2 (5%) 17 (5%)
- Other 0 (0%) 3 (1%)
Therapies administered concomitantly
- Corticosteroids 35 (95%) 277 (90%) 0.554
- Cyclophosphamide 8 (22%) 95 (31%) 0.342
- Mycophenolate 5 (13%) 17 (5%) 0.073
- Azathioprine 0 (0%) 16 (5%) 0.235
- Methotrexate 5 (13%) 36 (12%) 0.788
- Cyclosporin A/Tacrolimus 5 (13%) 14 (5%) 0.041
- Intravenous immunoglobulins 2 (5%) 12 (4%) 0.653
Time of exposure to biological (person-years)
- Total time 17.59 ± 2.16 17.23 ± 0.75 0.873
- Exposure to rituximab 15.13 ± 1.63 14.07 ± 0.47 0.471
- Exposure to infliximab 26.25 ± 15.4 15.27 ± 1.74 0.124
- Exposure to etanercept 12.50 ± 8.50 29.35 ± 3.84 0.246
- Exposure to adalimumab 26.00 ± 9.00 13.95 ± 2.52 0.183
*Statistically significant in the Cox regression multivariate model (hazard ratio 1.026, 95% confidence interval 1.005 to 1.047, P = 0.014).
Díaz-Lagares et al. Arthritis Research & Therapy 2011, 13:R112
http://arthritis-research.com/content/13/4/R112
Page 6 of 10introduction, rituximab has been increasingly used in
patients with SAD and there are more than 1,000
reported cases [22], overwhelmingly from uncontrolled
studies and case reports. However, the percentage and
rates of severe infections are unclear. The results of five
reported RCTs in SAD patients treated with rituximab
[ 3 - 7 ]s h o w e dap e r c e n t a g eo fs e v e r ei n f e c t i o n so f1 0 % ,
very similar to that found in patients receiving placebo
(12%) (Table 4) and the results of this study (11%).
Recent data from the French AIR Registry [18] showed
a higher rate in 136 SLE patients treated with rituximab
(66 severe infections per 1,000 person-years), similar to
the rate found in our SLE patients (63 per 1,000 person-
years). Our study is the first to analyze rates of severe
infection in patients with a wide variety of SAD. We
found the highest rates for vasculitis and inflammatory
myopathies (147 and 116 per 1,000 person-years, respec-
tively) and the lowest rate for Behçet disease (30 per
1,000 person-years). In addition, we found that the rates
of severe infection differed according to the number of
rituximab courses received, with a significantly increased
risk in patients receiving three or more courses of
rituximab.
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Figure 1 Cumulative survival rate (%) in patients with systemic
autoimmune diseases treated off-label with biologic agents
(Kaplan-Meier plots) according to the development of
infections. Broken line + crosses = infected patients Continuous
line + triangles = non-infected patients.
Table 4 Meta-analysis of adverse events in randomized controlled trials of biological agents in patients with systemic
autoimmune diseases
Disease Patients (n) Total side effects (n) Total infections (n) Severe infections (n)
Placebo Biologic Placebo Biologic Placebo Biologic Placebo Biologic
Meijer et al [3] Sjögren síndrome 10 20 4 16 4 11 NS NS
Dass et al [4] Sjögren síndrome 9 8 0 4 0 1 0 1
Merrill et al [5] SLE 88 169 73 139 15 16 15 16
Stone et al [6] ANCA-vasculitis 98 99 33 31 NS NS 7 7
Jones et al [7] ANCA-vasculitis 11 33 NS NS 7 19 3 7
RITUXIMAB 216 329 110/205 190/296 26/118 47/230 25/206 31/309
HR 1.55 (1.06-2.26)* HR 0.97 (0.80-1.17) HR 0.81 (0.45-1.48)
Hoffman et al [8] Giant cell arteritis 16 28 15 26 9 20 1 3
Salvarani et al [9] Rheumatic polym. 28 23 5 7 0 1 0 1
Baughman et al [10] Sarcoidosis 44 89 41 80 32 54 4 10
Mariette et al [11] Sjögren síndrome 49 54 1 6 0 1 0 1
INFLIXIMAB 137 194 62 (45.2% 119 (61.3%) 41 76 5 15
HR 1.92 (1.20-3.06)* HR 1.51 (0.92-2.47) HR 2.21 (0.74-7.96)
Melikoglu et al [12] Behcet 20 20 0 2 0 0 0 0
Baughman et al [13] Sarcoidosis 9 9 5 2 2 2 0 0
Sankar et al [14] Sjögren syndrome 14 14 1 2 1 0 0 0
WGET [15] ANCA-vasculitis 91 89 51 51 45 44 NS NS
Mtnez-Taboada et al [16] Giant cell arteritis 9 8 7 8 4 4 0 0
ETANERCEPT 143 140 64 (44.7%) 65 (46.4%) 52 (36.4%) 50 (35.7%) 0 (0%) 0 (0%)
HR 1.07 (0.65-1.75) HR 0.97 (0.58-1.63) Not calculable
TOTAL 496 663 236/485
(48.7%)
374/630
(59.4%)
119/398
(29.9%)
173/564
(30.7%)
30/395
(7.6%)
46/554
(8.3%)
HR 1.54 (1.20-1.97)* HR 1.04 (0.78-1.39) HR 1.10 (0.67-1.84)
*P < 0.05; ANCA, anti-neutrophil antibodies; HR, hazard ratio; NS, not specified; SLE, systemic lupus erythematosus.
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Page 7 of 10The rate of severe infections in SAD patients treated
with anti-TNF agents was 54 per 1,000 person-years,
and was much higher for the monoclonal antibodies
(infliximab and adalimumab) than for the soluble recep-
tor (etanercept), in line with some recent studies sug-
gesting a lower rate of infections in patients treated with
etanercept [23,24]. These rates are very similar to those
reported in RCTs and postmarketing studies in patients
with RA, which range between 17 and 64 per 1,000 per-
son-years [25-30], although the differences between
rheumatoid arthritis and the SAD studied here makes it
difficult to compare infection rates. Infection of the
lower respiratory or urinary tracts together with bactere-
mia/sepsis accounted for 75% of severe infections in our
patients, with a microorganism being identified in more
than 50% of episodes. Two patients treated with rituxi-
mab and no patients treated with anti-TNF agents
developed tuberculosis. No patient developed progres-
sive multifocal leukoencephalopathy.
One of the objectives of this study was to identify pos-
sible baseline risk factors for the development of severe
infections in SAD patients treated with biologic agents.
In patients with RA, identified risk factors for severe
infection include age, extraarticular involvement, leuko-
penia, low baseline IgG levels, corticosteroid dosage, and
comorbidities [31-34]. The largest prospective study [34]
identified older age, rheumatoid arthritis-related extraar-
ticular involvement, chronic lung disease and/or heart
failure, and IgG levels below 6 g/L as independent vari-
ables associated with severe infections. Although the dif-
ferences between this study and our results are
significant (design, disease evaluated, drug licensed, and
variables analyzed), it is noteworthy that both studies
identified age as an independent variable associated with
an increased risk of infection. However, we found no
association between previous or concomitant use of cor-
ticosteroids and other immunosuppressive agents (cyclo-
phosphamide, mycophenolate, methotrexate, or
azathioprine) and an increased risk of severe infection.
Possible concerns in observational studies include
selection bias (in our study, only refractory/severe
patients were included). This patient profile makes it
impossible to compare our results with those of con-
trolled studies, a bias that, in our opinion, is very diffi-
cult to avoid due to the lack of licensing for biologic
agents in autoimmune diseases. In addition, the lack of
a control group of SAD patients treated with non-biolo-
gic therapies did not permit the risk of infection to be
compared. However, in contrast to rheumatoid arthritis,
it is very difficult to design a case-control study in this
setting (SAD patients with life-threatening situations or
refractory to standard therapies). Our study has other
limitations, including the lack of evaluation of some
baseline factors that could influence the risk of
infection, such as laboratory parameters (neutrophil/
lymphocyte counts, serum IgG levels), corticosteroid
dosage, and baseline disease activity. However, our
population study (patients with refractory disease or life-
threatening situations) defines per se a group of patients
with a high baseline disease activity and, in fact, re-ana-
lysis showed no significant differences between the
crude rate of infection in these two groups. Neverthe-
less, in spite of these limitations, we believe that the
recruitment of nearly 350 patients with SAD treated off-
label with biologic agents is significant and permits use-
ful information on the characteristics and rates of severe
infection associated with the off-label use of biologic
agents in patients with severe, refractory disease to be
obtained.
Conclusions
In conclusion, we found a crude rate of severe infection
of 91 events per 1,000 person-years in a large series of
patients with SAD treated off-label with biologic thera-
pies, with the highest rate being observed for rituximab
and the lowest for etanercept. The only predictive factor
independently associated with severe infection was age.
Although awaiting the licensing of biologic agents for
SAD, an assessment of the risk of serious adverse events
versus the benefits of treatment should be made on an
individual basis.
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